Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors.
Adult
Age Factors
Carcinoma
/ etiology
Case-Control Studies
Databases, Factual
Female
Humans
Immunosuppressive Agents
/ therapeutic use
Inflammatory Bowel Diseases
/ complications
Laryngeal Neoplasms
/ etiology
Male
Middle Aged
Netherlands
/ epidemiology
Outcome Assessment, Health Care
Retrospective Studies
Risk Factors
Sex Factors
head and neck cancer
immunosuppressive therapy
inflammatory bowel diseases
laryngeal carcinoma
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
18 06 2020
18 06 2020
Historique:
received:
10
07
2019
pubmed:
29
9
2019
medline:
10
9
2021
entrez:
28
9
2019
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD) patients are at increased risk for developing extra-intestinal malignancies, mainly due to immunosuppressive medication. The risk of developing head and neck cancer in immunosuppressed transplant patients is increased. The relation between IBD patients and laryngeal cancer (LC) remains unclear. We aimed (1) to identify risk factors in IBD patients for LC development and (2) to compare clinical characteristics, outcome, and survival of LC in IBD patients with the general population. All IBD patients with LC (1993-2011) were retrospectively identified using the Dutch Pathology Database. We performed 2 case-control studies: (1) to identify risk factors, we compared patients with IBD and LC (cases) with the general IBD population; (2) to analyze LC survival, we compared cases with controls from the general LC population. We included 55 cases, 1800 IBD controls, and 2018 LC controls. Cases were more frequently male compared with IBD controls (P < 0.001). For ulcerative colitis (UC), cases were older at IBD diagnosis (P < 0.001). Crohn's disease (CD) cases were more frequently tobacco users (P < 0.001) and more often had stricturing (P = 0.006) and penetrating (P = 0.008) disease. We found no survival difference. Immunosuppressive medication had no impact on survival. Male sex was a risk factor for LC in IBD patients. Older age at IBD diagnosis was a risk factor for UC to develop LC. Tobacco use and stricturing and penetrating disease were risk factors for LC development in CD patients. Inflammatory bowel disease was not associated with impaired survival of LC. Immunosuppressive medication had no influence on survival.
Sections du résumé
BACKGROUND
Inflammatory bowel disease (IBD) patients are at increased risk for developing extra-intestinal malignancies, mainly due to immunosuppressive medication. The risk of developing head and neck cancer in immunosuppressed transplant patients is increased. The relation between IBD patients and laryngeal cancer (LC) remains unclear. We aimed (1) to identify risk factors in IBD patients for LC development and (2) to compare clinical characteristics, outcome, and survival of LC in IBD patients with the general population.
METHODS
All IBD patients with LC (1993-2011) were retrospectively identified using the Dutch Pathology Database. We performed 2 case-control studies: (1) to identify risk factors, we compared patients with IBD and LC (cases) with the general IBD population; (2) to analyze LC survival, we compared cases with controls from the general LC population.
RESULTS
We included 55 cases, 1800 IBD controls, and 2018 LC controls. Cases were more frequently male compared with IBD controls (P < 0.001). For ulcerative colitis (UC), cases were older at IBD diagnosis (P < 0.001). Crohn's disease (CD) cases were more frequently tobacco users (P < 0.001) and more often had stricturing (P = 0.006) and penetrating (P = 0.008) disease. We found no survival difference. Immunosuppressive medication had no impact on survival.
CONCLUSIONS
Male sex was a risk factor for LC in IBD patients. Older age at IBD diagnosis was a risk factor for UC to develop LC. Tobacco use and stricturing and penetrating disease were risk factors for LC development in CD patients. Inflammatory bowel disease was not associated with impaired survival of LC. Immunosuppressive medication had no influence on survival.
Identifiants
pubmed: 31559415
pii: 5574717
doi: 10.1093/ibd/izz210
pmc: PMC7301406
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1060-1067Informations de copyright
© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2845-2851
pubmed: 30362311
J Crohns Colitis. 2012 Aug;6(7):792-5
pubmed: 22464812
Inflamm Bowel Dis. 2018 Aug 16;24(9):2015-2026
pubmed: 30759216
Dig Endosc. 2018 Mar;30(2):236-244
pubmed: 28836702
Int J Epidemiol. 2017 Apr 1;46(2):e7
pubmed: 26045509
Int J Oncol. 2014 Jun;44(6):1799-805
pubmed: 24676623
Aliment Pharmacol Ther. 2018 Mar;47(5):605-614
pubmed: 29369387
J Crohns Colitis. 2015 Nov;9(11):945-65
pubmed: 26294789
Gut. 2012 Apr;61(4):476-83
pubmed: 22157331
Inflamm Bowel Dis. 2010 Sep;16(9):1541-9
pubmed: 20155846
Dig Dis. 2009;27(3):375-81
pubmed: 19786768
Transplant Proc. 2009 Jul-Aug;41(6):2447-9
pubmed: 19715947
Inflamm Bowel Dis. 2011 Mar;17(3):802-8
pubmed: 20848547
Br J Cancer. 2003 Oct 6;89(7):1221-7
pubmed: 14520450
Am J Gastroenterol. 2010 Jul;105(7):1480-7
pubmed: 20332773
Gastroenterology. 2004 Feb;126(2):451-9
pubmed: 14762782
Drug Saf. 2000 Aug;23(2):101-13
pubmed: 10945373
Head Neck. 2009 Mar;31(3):406-11
pubmed: 18704962
Transplant Proc. 2015 Oct;47(8):2483-7
pubmed: 26518956
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Drugs. 2007;67(8):1167-98
pubmed: 17521218
J Gastroenterol. 2012 Dec;47(12):1308-22
pubmed: 22627504
Gut. 2001 Apr;48(4):526-35
pubmed: 11247898
Am J Med. 1985 Jan 21;78(1A):44-9
pubmed: 3970040
J Gastrointestin Liver Dis. 2016 Dec;25(4):431-440
pubmed: 27981298
Maturitas. 2018 Apr;110:71-78
pubmed: 29563038
BMC Cancer. 2018 Oct 20;18(1):1005
pubmed: 30342481
Gut. 2006 Feb;55(2):228-33
pubmed: 16120759
Inflamm Bowel Dis. 2015 Mar;21(3):674-98
pubmed: 25545375
Gut. 2014 Mar;63(3):423-32
pubmed: 23408350
JAMA. 2017 Nov 7;318(17):1679-1686
pubmed: 29114832
Eur J Gastroenterol Hepatol. 2003 Feb;15(2):185-7
pubmed: 12560764
Oncotarget. 2015 Nov 10;6(35):38336-47
pubmed: 26447542
Inflamm Bowel Dis. 2017 Nov;23(11):2018-2026
pubmed: 28837522
Head Neck. 2002 Apr;24(4):319-25
pubmed: 11933172
Anticancer Drugs. 2016 Jun;27(5):470-3
pubmed: 26908347
Transplant Proc. 2013 Sep;45(7):2733-5
pubmed: 24034035
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):541-50
pubmed: 19190158
Inflamm Bowel Dis. 2009 Jan;15(1):9-16
pubmed: 18618636
Oral Dis. 2016 May;22(4):260-4
pubmed: 26671147